Please login to the form below

Not currently logged in
Email:
Password:

IFPMA appoints Fumie Griego as assistant director general

She joins the global pharma association from Merck KGaA

Fumie GriegoGlobal pharma association the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) has appointed Femie Griego to be its new assistant director general.

She joins from Merck KGaA, where she held senior roles such as head of global oncology policy and strategy, global government affairs policy and has also served as vice president for international health policy at Pharmaceutical Research and Manufacturers of America (PhRMA).

Prior to that Griego spent time at the White House as its senior economist where she provided US officials in both the Bush and Obama administrations with advice on a range of health and policy issues.

Thomas Cueni, director-general at IFPMA, said: “I am delighted to count on the support of Fumie Griego, a highly competent professional, whom I have chosen for her strong pharma expertise and background in global affairs, including intellectual property protection, pricing, costs, value issues and health diplomacy.

“She will be a strong asset to help IFPMA bring thought leadership in addressing global health challenges.”

Griego will join IFPMA's leadership team and will also be working on strengthening the association's work on the industry’s value proposition.

11th May 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...